Actualités Corvus Pharmaceuticals Inc - CRVS | Actions NASDAQ

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023

BURLINGAME, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a...

Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting

Preclinical data supports targeting ITK as a new approach for cancer immunotherapy Novel mechanism of action...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Current Report Filing (8-k)

0001626971 false 0001626971 2023-03-29 2023-03-29 iso4217:USD xbrli:shares...

CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma

Interim data from Phase 1/1b clinical trial of CPI-818, including new evidence supporting the recently...

Current Report Filing (8-k)

false 0001626971 0001626971 2023-03-28 2023-03-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Securities Registration Statement (simplified Form) (s-3)

Table of Contents As filed with the Securities and Exchange Commission on March 28, 2023...

Annual Report (10-k)

0.891.030.204655351141854110294788784655351141854110294788780.891.030.201995000465535110000016269712021FYfalse24...

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

New CPI-818 Predictive Biomarker Enables Selection of Lymphoma Patients Most Likely to Benefit from Treatment...

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023

BURLINGAME, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a...

Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting

BURLINGAME, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a...

Current Report Filing (8-k)

0001626971 false 0001626971 2023-03-10 2023-03-10 iso4217:USD xbrli:shares...

Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal

Findings may provide a treatment that enables discontinuation of HIV antiretroviral therapy by preventing...

Amended Statement of Ownership (sc 13g/a)

Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A ...

Statement of Ownership (sc 13g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Corvus Pharmaceuticals Inc (CRVS)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

CRVS Actualités

Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023

Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma

Current Report Filing (8-k)

Securities Registration Statement (simplified Form) (s-3)

Annual Report (10-k)

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023

Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting

Current Report Filing (8-k)

Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal

Amended Statement of Ownership (sc 13g/a)

Statement of Ownership (sc 13g)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Corvus Pharmaceuticals Inc (CRVS) Actualités

Corvus Pharmaceuticals Inc (CRVS)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

CRVS Actualités

Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023

Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma

Current Report Filing (8-k)

Securities Registration Statement (simplified Form) (s-3)

Annual Report (10-k)

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023

Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting

Current Report Filing (8-k)

Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal

Amended Statement of Ownership (sc 13g/a)

Statement of Ownership (sc 13g)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application